Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1203-1210

  Shurrab, Mohammed ^a   Morillo, Carlos A ^b   Schulman, Sam ^b   Kansal, Nitin ^b   Danon, Asaf ^a   Newman, David ^a   Lashevsky, Ilan ^a   Healey, Jeff S ^b   Crystal, Eugene ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CARDIAC PATIENT; CATHETER ABLATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS PERFORATION; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOMA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; HUMANS; PERIOPERATIVE CARE; STROKE; WARFARIN;

EID: 84884594868     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.07.005     Document Type: Review

References (36)

1. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
2. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation 2011, 123:E269-E367.
3. Calkins H., Kuck K.H., Cappato R., et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012, 9. 632-96.e21.
4. Santangeli P., Di Biase L., Horton R., et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012, 5:302-311.
5. Wann L.S., Curtis A.B., Ellenbogen K.A., et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:1144-1150.
6. Wells GA, Shea B, O'Connell D, etal. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: Accessed April 21, 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available at: Accessed April 9, 2013. http://handbook.cochrane.org/.
9. Kaiser D.W., Streur M.M., Nagarakanti R., Whalen S.P., Ellis C.R. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol 2013, 37:241-247.
10. Konduru S.V., Cheema A.A., Jones P., Li Y., Ramza B., Wimmer A.P. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. JInterv Card Electrophysiol 2012, 35:277-284.
11. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. JAm Coll Cardiol 2012, 59:1168-1174.
12. Snipelisky D., Kauffman C., Prussak K., Johns G., Venkatachalam K., Kusumoto F. Acomparison of bleeding complications post-ablation between warfarin and dabigatran. JInterv Card Electrophysiol 2012, 35:29-33.
13. Bassiouny M, Saliba W, Rickard J, etal. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013;6:460-6.
14. Imamura K., Yoshida A., Takei A., et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol 2013, 37:223-231.
15. Kim J.S., She F., Jongnarangsin K., et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013, 10:483-489.
16. Maddox W., Kay G.N., Yamada T., et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. JCardiovasc Electrophysiol 2013, 24:861-865.
17. Nin T., Sairaku A., Yoshida Y., et al. Arandomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013, 36:172-179.
18. Yamaji H., Murakami T., Hina K., et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013, 33:409-418.
19. Kaseno K., Naito S., Nakamura K., et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012, 76:2337-2342.
20. Winkle R.A., Mead R.H., Engel G., Kong M.H., Patrawala R.A. The use of dabigatran immediately after atrial fibrillation ablation. JCardiovasc Electrophysiol 2012, 23:264-268.
21. Viles-Gonzalez J.F., Mehta D. Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. Curr Cardiol Rep 2011, 13:38-42.
22. Cappato R., Calkins H., Chen S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:32-38.
23. Gaita F., Caponi D., Pianelli M., et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010, 122:1667-1673.
24. Schrickel J.W., Lickfett L., Lewalter T., et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010, 12:52-57.
25. Natale A., Raviele A., Arentz T., et al. Venice Chart international consensus document on atrial fibrillation ablation. JCardiovasc Electrophysiol 2007, 18:560-580.
26. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
27. Kim J.S., Jongnarangsin K., Latchamsetty R., et al. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 2013, 6:302-309.
28. Mardigyan V., Verma A., Birnie D., et al. Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol 2013, 29:219-223.
29. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
30. Stangier J., Stahle H., Rathgen K., Roth W., Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. JClin Pharmacol 2008, 48:1411-1419.
31. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
32. Siegal D.M., Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. JThromb Thrombolysis 2013, 35:391-398.
33. Hsu L.F., Jais P., Hocini M., et al. Incidence and prevention of cardiac tamponade complicating ablation for atrial fibrillation. Pacing Clin Electrophysiol 2005, 28:S106-S109.
34. Latchamsetty R., Gautam S., Bhakta D., et al. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 2011, 8:805-808.
35. Knight B.P. Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?. JAm Coll Cardiol 2012, 59:1175-1177.
36. Verma A., Tsang B. The use of anticoagulation during the periprocedure period of atrial fibrillation ablation. Curr Opin Cardiol 2012, 27:55-61.